Literature DB >> 30059719

Traditional Chinese herbal injection: Current status and future perspectives.

Haona Li1, Siwang Wang2, Zhihua Yue3, Xuequn Ren4, Jielai Xia5.   

Abstract

Traditional Chinese herbal injection, frequently referred to as TCM injection, has evolved over 70 years as a treatment modality that parallels injections of pharmaceutical products. As the market reach has not been analyzed systematically in the past literature this article performed a descriptive analysis of various aspects of TCM injections based on the following data sources: (1) information retrieved from website of drug registration system of China, and (2) regulatory documents, annual reports and ADR Information Bulletins issued by drug regulatory authority. As of December 31, 2017, 134 generic names of TCM injections from 224 manufacturers were approved for sale. Only 5 of the 134 TCM injections are documented in the present version of Ch.P (2015). Most TCM injections are documented in drug standards other than Ch.P. The formulation, ingredients and routes of administration of TCM injections are more complex than conventional chemical injections. Ten TCM injections are covered by national lists of essential medicine and 58 are covered by China's basic insurance program (2017). ADR reports related to TCM injections accounts for >50% of all ADR reports related to TCMs and the percentages have been rising annually. Making traditional medicine injectable might be a promising way to develop traditional medicines. However, many practical challenges need to be overcome by further development before a brighter future for injectable traditional medicines can reasonably be expected.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adverse drug reaction; Complementary and alternative medicine; Traditional Chinese herbal injection; Traditional Chinese medicine

Mesh:

Substances:

Year:  2018        PMID: 30059719     DOI: 10.1016/j.fitote.2018.07.009

Source DB:  PubMed          Journal:  Fitoterapia        ISSN: 0367-326X            Impact factor:   2.882


  15 in total

Review 1.  Overuse of intravenous infusions in China: focusing on management platform and cultural problems.

Authors:  Shuangshuang Zeng; Dong Wang; Wanli Liu; Yuanliang Yan; Minwen Zhu; Zhicheng Gong; Shusen Sun
Journal:  Int J Clin Pharm       Date:  2019-08-30

Review 2.  Xiyanping Plus Azithromycin Chemotherapy in Pediatric Patients with Mycoplasma pneumoniae Pneumonia: A Systematic Review and Meta-Analysis of Efficacy and Safety.

Authors:  Qiao Li; Zhi-Yong Li; Jie Zhang; Wen-Na Guo; Xiao-Meng Xu; Fa-Xin Sun; Hui Xu
Journal:  Evid Based Complement Alternat Med       Date:  2019-08-29       Impact factor: 2.629

3.  Identification of high-risk patients for ADR induced by traditional Chinese medicine injection: a nested case-control study.

Authors:  Cheng Jiang; Jie Shen; Dan Shou; Nani Wang; Jing Jing; Guodi Zhang; Jing Gu; Yunlong Tian; Caihua Sun; Jiaqi He; Jiaqi Ma; Xiaojun Wang; Gonghua Li
Journal:  Sci Rep       Date:  2019-11-13       Impact factor: 4.379

Review 4.  The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence.

Authors:  Dan Zhang; Bing Zhang; Jin-Tao Lv; Ri-Na Sa; Xiao-Meng Zhang; Zhi-Jian Lin
Journal:  Pharmacol Res       Date:  2020-05-05       Impact factor: 7.658

5.  Assesment of Adulterated Traditional Chinese Medicines in China: 2003-2017.

Authors:  Mingzhe Xu; Baobin Huang; Fang Gao; Chenchen Zhai; Yueying Yang; Lulu Li; Wenya Wang; Luwen Shi
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

Review 6.  Applying regulatory science in traditional chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications.

Authors:  Zuanji Liang; Yunfeng Lai; Meng Li; Junnan Shi; Chi Ieong Lei; Hao Hu; Carolina Oi Lam Ung
Journal:  Chin Med       Date:  2021-02-16       Impact factor: 5.455

7.  Safety of traditional Chinese medicine injection based on spontaneous reporting system from 2014 to 2019 in Hubei Province, China.

Authors:  Linhui Yang; Xiaofang Shangguan; Rui Huang; Yuanxuan Cai; Bishwajit Ghose; Shangfeng Tang
Journal:  Sci Rep       Date:  2021-04-23       Impact factor: 4.379

Review 8.  Immunomodulatory drug discovery from herbal medicines: Insights from organ-specific activity and xenobiotic defenses.

Authors:  Jue Shi; Jui-Hsia Weng; Timothy J Mitchison
Journal:  Elife       Date:  2021-11-15       Impact factor: 8.140

9.  Integrating Study on Qualitative and Quantitative Characterization of the Major Constituents in Shuanghuanglian Injection with UHPLC/Q-Orbitrap-MS and UPLC-PDA.

Authors:  Gen Xue; Meijuan Zhu; Ning Meng; Jianli Guan; Jide Zhang; Jing Yang; Yuefei Wang; Ying Cui; Xin Chai
Journal:  J Anal Methods Chem       Date:  2021-05-21       Impact factor: 2.193

10.  Serious Concerns About the RCT Study Quality of Traditional Chinese Medicine Injections for Treating Cardiovascular Diseases and COVID-19.

Authors:  Guoying Gao; Siu-Wai Leung; Yongliang Jia
Journal:  Cardiovasc Drugs Ther       Date:  2020-08-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.